10-K: Keen Vision Faces Going Concern Amid Reduced Trust, New Merger LOI

Keen Vision Acquisition Corporation reports a significant reduction in its trust account balance due to redemptions and a going concern warning, while pursuing a new, smaller business combination target.

Summary

• Keen Vision Acquisition Corporation (KVAC) is a blank check company incorporated in the British Virgin Islands, formed to effect a business combination.
• The company consummated its Initial Public Offering (IPO) on July 27, 2023, raising $149.5 million from 14,950,000 units at $10.00 per unit, with an additional $6,785,750 from a private placement to its sponsor.
• A total of $151,368,750 was initially deposited into a trust account for the benefit of public shareholders.
• The company initially entered into a Merger Agreement with Medera Inc. on September 3, 2024, for an aggregate consideration of $622,560,000, which was subsequently terminated.
• On February 26, 2026, KVAC entered into a binding Letter of Intent (LOI) with Novoheart Group Limited (NVH), a wholly-owned subsidiary of Medera, setting NVH's enterprise valuation at US$100,000,000.
• The LOI requires the surviving company to have at least US$10,000,000 in available cash at closing, after transaction expenses and NVH liabilities.
• Public shareholders have redeemed a significant number of shares: 8,545,348 shares for $92,398,989 on October 25, 2024; 1,582,306 shares for $18,091,743 on July 22, 2025; and 3,781,900 shares tendered for redemption on January 22, 2026.
• As of December 31, 2025, the company had cash of $11,206 and investments in the Trust Account of $57,003,115, with a working capital deficit of $4,020,642.
• Net income for the year ended December 31, 2025, was $1,910,263, primarily from dividend and interest income from the Trust Account, a decrease from $7,409,180 in 2024.
• The company has extended its deadline to complete a business combination multiple times, with the current deadline being April 27, 2026.
• The independent auditor has raised substantial doubt about the company's ability to continue as a going concern if a business combination is not consummated by April 27, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing with a highly negative sentiment due to the termination of a major merger, the significant reduction in trust assets from redemptions, the 'going concern' warning, and the tight deadline for a new, smaller deal, all pointing to substantial operational and financial challenges.

Positives

• Management team possesses extensive global networks and experience in biotech, agriculture, consumer goods, and cross-border M&A, which are crucial for identifying and executing business combinations.
• The company has identified a new target, Novoheart Group Limited (NVH), in the pre-clinical human disease modeling and drug discovery sector, aligning with its biotech focus.
• The LOI with NVH includes a minimum available cash requirement of US$10,000,000 at closing, providing some financial clarity for the potential combined entity.

Negatives

• The original Merger Agreement with Medera Inc. for $622.56 million was terminated, indicating a significant setback in the initial business combination plan.
• The new target, Novoheart Group Limited (NVH), has an enterprise valuation of US$100,000,000, which is substantially lower than the previously targeted Medera Inc., suggesting a downsized acquisition.
• Significant shareholder redemptions have drastically reduced the funds in the Trust Account from an initial $151,368,750 to $57,003,115 as of December 31, 2025, impacting the capital available for a business combination.
• The company reported a working capital deficit of $4,020,642 as of December 31, 2025, and the independent auditor has expressed substantial doubt about its ability to continue as a going concern.
• Net income decreased from $7,409,180 in 2024 to $1,910,263 in 2025, primarily due to reduced dividend and interest income from the Trust Account following redemptions.
• The company has repeatedly extended its business combination deadline, incurring additional costs and potentially signaling difficulties in securing a suitable target.

Risks

• Inability to complete the initial business combination within the extended deadline of April 27, 2026, which would lead to liquidation and warrants expiring worthless.
• Substantial doubt about the company's ability to continue as a going concern due to significant working capital deficiency and the need to raise additional funds.
• Potential for claims by creditors to reduce the amounts in the Trust Account, leading to a per-share redemption price less than the initial $10.125.
• Conflicts of interest among officers and directors who have pre-existing fiduciary or contractual obligations to other entities, potentially diverting attractive business opportunities.
• Lack of business diversification, as success is dependent on the future performance of a single acquired business.
• Limited ability to evaluate the target business management, and uncertainty regarding the future management's skills to manage a public company.
• Shareholders may not have the ability to approve an initial business combination if the company proceeds with a tender offer instead of a shareholder vote.
• Potential risks associated with acquiring a China-based company, including PRC laws and regulations, governmental interference, and difficulties in enforcing civil liability.
• Reliance on third parties for cybersecurity, with limited internal resources to protect against or remediate cyber incidents.

Future Outlook

The company intends to complete a business combination with Novoheart Group Limited (NVH) by April 27, 2026, following the negotiation and execution of a Replacement Merger Agreement by April 10, 2026. The combined entity is expected to have at least US$10,000,000 in available cash at closing. The company's ability to continue as a going concern is contingent upon successfully consummating this business combination.

Management Comments

• Our management team has genuine global reach and resources that will enable our target to expand its geographical footprint, thereby increasing profit potentials as well as optimizing its performance as a publicly listed entity in the market.
• We believe our management team's personnel, network and relationships combined with their entrepreneurial vision, unique and diversified experiences in investing, operating and transforming businesses will uniquely position them to identify and execute attractive business combination opportunities.
• We intend to focus on companies that we believe have strong growth capacity and expertise compatible with our management team's expertise, to accelerate growth and enhance public market performance.
• We understand that a selective, yet efficient business combination process is critical in enhancing the investment return for our investors. With the extensive experience of our board members, we believe we are well positioned to achieve a successful de-SPAC in a timely manner.

Industry Context

StockSavvy.ai notes that Keen Vision Acquisition Corporation operates within the highly competitive SPAC market, which has seen increased scrutiny and redemptions in recent years. The shift from a larger, $622.56 million target (Medera) to a smaller, $100 million target (Novoheart Group Limited) reflects the challenging environment for SPACs to secure and close large-scale deals. The focus on biotechnology, specifically pre-clinical human disease modeling and drug discovery, aligns with a growing, yet capital-intensive and high-risk, sector. The repeated extensions and significant redemptions are common indicators of SPACs struggling to find suitable targets or maintain investor confidence, potentially making it harder to compete with more established private equity or venture capital firms for attractive assets.

Comparison to Industry Standards

• The significant redemptions experienced by Keen Vision Acquisition Corporation, reducing its trust account from over $151 million to approximately $57 million, are indicative of a broader trend in the SPAC market where high redemption rates have become common, often exceeding 50% or more, as investors opt for cash back rather than participating in uncertain de-SPAC transactions.
• The termination of the initial merger agreement with Medera Inc. and the subsequent LOI with Novoheart Group Limited at a substantially lower valuation ($100 million vs. $622.56 million) suggests a struggle to secure a high-value target, a challenge many SPACs face in a more discerning market compared to the SPAC boom years.
• The repeated extensions of the business combination deadline, funded by sponsor loans, are a common tactic for SPACs nearing their expiration, but they also signal prolonged uncertainty and can erode investor confidence, similar to other SPACs like Gores Holdings VIII (GIIX) or Churchill Capital Corp IV (CCIV) which faced extended timelines and investor skepticism during their search for targets.

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or other legal proceedings.

Related Party Transactions

• KVC Sponsor LLC (the Sponsor) purchased 678,575 private units for $6,785,750 simultaneously with the IPO.
• The company pays KVC Sponsor LLC $10,000 per month for general and administrative services, including office space, utilities, and administrative support, commencing August 1, 2023.
• The Sponsor has provided unsecured promissory notes totaling $2,668,022 as of December 31, 2025, to extend the business combination period, which are non-interest bearing and convertible into private units at the lender's discretion upon business combination.
• As of December 31, 2025, there was a temporary advance of $1,315,880 from the Sponsor, which is unsecured, interest-free, and has no fixed terms of repayment.
• Officers and directors have agreed to vote their shares in favor of any proposed business combination and waive redemption rights for their insider shares and private units.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity issuances (e.g., PIPE) and the conversion of sponsor loans into private units.
• Public shareholders who have not redeemed their shares face uncertainty regarding the completion of the business combination and the value of their investment, especially given the 'going concern' warning and the reduced trust account.
• Employees (post-business combination) will be impacted by the integration of the target company and the strategic direction set by the new combined entity's management.
• Creditors face the risk that claims against the company could reduce the funds available in the Trust Account for public shareholders if the company liquidates without a business combination, despite the sponsor's agreement to be liable under certain conditions.

Next Steps

• Negotiate and execute a Replacement Merger Agreement with Novoheart Group Limited (NVH) no later than April 10, 2026.
• Seek approval from respective boards of directors and shareholders for the transactions contemplated by the LOI with NVH.
• Consummate the initial business combination by April 27, 2026, to avoid liquidation and address the going concern warning.
• Potentially pursue a Private Investment in Public Equity (PIPE) fundraising to meet the minimum cash requirement for the NVH business combination.

Key Dates

Recommendation

The termination of a large, previously announced merger, coupled with a significant reduction in the trust account due to high redemptions, signals severe challenges and a loss of investor confidence. The 'going concern' warning from the auditor underscores the existential risk. While a new, smaller LOI has been signed, the tight deadlines and the company's precarious financial position make the successful completion of any deal highly uncertain. Seasoned investors would likely view these developments as a strong indication to exit their positions due to the elevated risk of liquidation and potential loss of capital.

Keywords

SPAC, blank check company, business combination, Novoheart Group Limited, NVH, Medera Inc., biotechnology, drug discovery, redemptions, trust account, going concern, SEC filing, 10-K, corporate governance, financial reporting, Nasdaq